Deutsche Bank Ag\ Curis Inc Transaction History

Deutsche Bank Ag\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.71 - $2.43 $307,459 - $1.05 Million	-433,042 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $775,972 - $1.72 Million	335,919 Added 345.87%	433,042 $1.03 Million
Q4 2021 Feb 11, 2022	SELL	$4.45 - $8.09 $47,267 - $85,931	-10,622 Reduced 9.86%	97,123 $462,000
Q3 2021 Nov 04, 2021	BUY	$6.94 - $8.85 $57,754 - $73,649	8,322 Added 8.37%	107,745 $844,000
Q2 2021 Aug 11, 2021	SELL	$7.45 - $16.27 $6,719 - $14,675	-902 Reduced 0.9%	99,423 $802,000
Q1 2021 May 13, 2021	BUY	$8.78 - $12.8 $880,853 - $1.28 Million	100,325 New	100,325 $1.14 Million
Q1 2019 May 15, 2019	SELL	$0.78 - $2.01 $826 - $2,130	-1,060 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$0.62 - $2.25 $2,954 - $10,723	-4,766 Reduced 81.81%	1,060 $0
Q3 2018 Dec 21, 2021	BUY	$1.38 - $1.94 $6,553 - $9,213	4,749 Added 440.95%	5,826 $10,000
Q3 2018 Nov 14, 2018	SELL	$1.38 - $1.94 $27,380 - $38,491	-19,841 Reduced 94.85%	1,077 $1,000
Q2 2018 Apr 21, 2020	BUY	$1.73 - $3.35 $7,368 - $14,267	4,259 Added 25.57%	20,918 $36,000
Q2 2018 Aug 14, 2018	BUY	$1.73 - $3.35 $28,820 - $55,807	16,659 New	16,659 $27,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.